Ad www.AngelOne.in
FREE Account Opening + Zero AMC Fees* + MutualFund SIP1
FREE Equity Delivery and MF
Flat ₹20/trade Intra-day/F&O
Ad www.AngelOne.in
Right Issue Status: Closed [31st Oct 2022 to 10th Nov 2022]
Suven Life Sciences Ltd Right issue will be open for subscription soon. The company will issue 1 right equity shares for every 2 fully paid-up equity shares held on the record date, 18 Oct 22. The face value per share is Rs 1 and the right issue price is fixed at Rs 55 per share. The issue will open for subscription from 31 Oct to 10 Nov 2022. Stay updated with us to know more about Suven Life Sciences Ltd's Right issue details 2022 including issue size, right issue entitlement, terms of payment, and more.
| Suven Life Sciences Issue Details | Values |
|---|---|
| Category | RightIssue |
| Right Issue Issue Size (Shares) | 72,691,239 |
| Right Issue Issue Size (Amount) | ₹399.80 Cr |
| Face Value | ₹1 Per Equity Share |
| Right Issue - Issue Price | ₹55 per share |
| Right Issue Record Date | 18th Oct 2022 |
| Right Issue Entitlement | 1 Rights Equity Share for every 2 Equity Shares held on the Record Date |
| Right Issue Terms of payment | The full amount of ₹55 per Rights Equity Share is payable on Application |
| Listing At | BSE, NSE |
| BSE Code | 530239 |
| NSE Code | SUVEN |
In this section we have covered all important dates related to Suven Life Sciences Right Issue. Dates are updated as they are announced. The most noted dates are Right Issue start date and Right Issue end date, which one should use to participate in Right Issue.
| Right Issue Activity | Date |
|---|---|
| Right Issue Issue Open Date | 31st Oct 2022 |
| Right Issue Issue Close Date | 10th Nov 2022 |
| Basis of Allotment Finalisation Date* | 18th Nov 2022 |
| Refunds Initiation* | 19th Nov 2022 |
| Credit of Shares to Demat Account* | 21st Nov 2022 |
| Right Issue Listing Date* | 24th Nov 2022 |
* - Tentative Dates
Zerodha Trade@20
Suven Life Sciences Ltd is a distinguished developer, Manufacturer and exporter of premium quality Pharmaceutical Raw Material, Active Pharmaceutical Ingredients and Intermediates. The company spreads at all the over the world including the highly competitive markets of European, Gulf and North/South American countries. It provides a wide range of Drug Discovery and Development Support Services (DDDSS) to global Pharma and Biotech companies.
The company's discovery research is focused on discovering and developing new chemical entities (NCEs), which are best-in-class central nervous system therapies for the treatment of cognitive disorders, major depressive disorders, sleep disorders, psychiatric disorders, pain and inflammation, gastro-intestinal motility disorders
Past performance and financial results of Suven Life Sciences.
| Suven Life Sciences Financials (₹ in Cr) | 31-Mar-2022 | 31-Mar-2021 |
|---|---|---|
| Total Assets | ₹108.03 | ₹128.42 |
| Total Revenue | ₹17.16 | ₹21.23 |
| Net Profit/Loss | ₹-122 | ₹-72.15 |
The table below is live update of Right Issue bidding details from NSE and BSE.
Suven Life Sciences Right Issue Offer Document (Letter of Offer) >>Document
Suven Life Sciences Right Issue Offer Document (Letter of Offer) >>Suven Life Sciences Right Issue Red Herring Prospectus is not yet available.
Suven Life Sciences Right Issue Online Application (Registrar & Transfer Agent) >>Online Application
Suven Life Sciences Right Issue Online Application (Registrar & Transfer Agent) >>Suven Life Sciences Right Issue RTA information is not yet available.
Last Updated on 2022-11-03T10:18:47+00:00
